South Korean biotech firm AngioLab has secured two government R&D grants totaling 880 million KRW to advance its proprietary SPACE (Skin Penetrating and Cell Entering) peptide-based delivery platform. The projects target functional cosmetic ingredients and macromolecule transdermal delivery, signaling new sourcing opportunities for overseas aesthetic buyers seeking innovative derma-cosmetic and bio-material technologies.
Government R&D grants
AngioLab announced on March 8 that it was selected for two government R&D projects, validating the technical merit and scalability of its SPACE peptide platform. The first project, under the SME Technology Innovation Development Program (K-Beauty track), focuses on developing next-generation functional cosmetic ingredients that enhance skin delivery efficiency of polymer and protein-based anti-aging materials. The second project, part of the Regional Innovation Leading Enterprise Development Program, explores applying SPACE peptides to recombinant proteins, antibody fragments, and mRNA for transdermal delivery.
Funding and timeline
For the K-Beauty project, AngioLab will receive 480 million KRW in government support through March 2028 to develop skin delivery technologies for macromolecules such as PDRN, collagen, and hyaluronic acid. The regional project will receive 400 million KRW over two years to validate preclinical transdermal delivery potential, efficacy, and safety of various biomaterials, aiming to create a licensable delivery platform.
Market strategy
AngioLab plans to pursue short-term entry into the derma-cosmetic market while expanding mid- to long-term into protein and mRNA-based biopharmaceutical delivery platforms. The company expects to generate preclinical data on functional cosmetic ingredient applicability and macromolecule delivery, then seek joint development and technology transfer opportunities with domestic and international cosmetic firms, biopharma developers, and derma-medical device companies.
What buyers should watch
Overseas importers and distributors of aesthetic ingredients and derma-cosmetic products should monitor AngioLab’s SPACE peptide platform for potential licensing or co-development deals. The technology could enable more effective delivery of active ingredients like collagen and hyaluronic acid in topical formulations, offering differentiation in the competitive K-beauty and medical aesthetics supply chain.
Company background
AngioLab also develops angiogenesis-inhibiting natural product drugs, antibody therapeutics, and functional food ingredients. Its wet age-related macular degeneration treatment ALS-L1023 has been licensed to a domestic pharmaceutical company and is in Phase 3 clinical trials. The company is leveraging this expertise to expand into skin and cell delivery platforms.
Source: Read the original report | Published: June 08, 2026